The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No merry xmas or happy new year to shareholders on twitter...................
https://twitter.com/apollon_uk
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=APOL
We seem to be loosing our position here
Apollon Formularies
@apollon_uk
·
1h
(2/2) #Apollon firmly believes in the benefits of #medicalcannabis for the treatment of various conditions and welcomes a more positive attitude across the UK and #Europe as we look for opportunities to expand our distribution
https://twitter.com/apollon_uk
12.1m trades … unusual ??
Apollon Formularies plc (AQSE: APOL), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, announces that it has been notified on 13th of September 2022, that Roderick ("Rod") Claude McIllree, Non-Executive Director, has transferred 10,000,000 Ordinary Shares for nil consideration to Stene Jacobs, Chief Operating Officer, on 13th of September 2022.
Following the transfer, Rod McIllree is interested in 207,485,940 Ordinary Shares representing approximately 26.9% of the issued share capital of the Company.
Following the transfer, Stene Jacobs is interested in 11,382,306 Ordinary Shares representing approximately 1.48% of the issued share capital of the Company.
https://www.investegate.co.uk/apollon-formularies--apol-/rns/directors--dealing/202209130700121849Z/
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=APOL
Apollon Formularies Plc
Chairman and CEO of Apollon is a Keynote speaker at the Cannabis Science Conference in Baltimore
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international pharmaceutical company trading on the Aquis Stock Exchange, is pleased to announce that Dr. Stephen Barnhill, Chairman and CEO of Apollon, is an invited keynote speaker at the Cannabis Science Conference ("CSC"), being held in Baltimore on 14-16 September 2022. Dr. Barnhill will deliver a presentation on the "Unique Combination of Cannabis and Mushrooms for the Treatment of Cancer" at 3:40 pm EDT/20:40 pm BST on 15 September.
CSC is the world's largest and fastest growing cannabis science event with a specialised focus on medical cannabis, analytical science, cultivation science, psychedelic science, hemp, and CBD. The conferences bring together a wide range of experts within the cannabis industry, including research scientists, medical practitioners, policy makers, instrument manufacturers and testing labs. The event aims to improve cannabis science and education. No new information related to Apollon will be released during the session.
Stephen Barnhill , MD, Chairman and CEO of Apollon Formularies plc , stated: "I am honoured to have been invited to address the upcoming Cannabis Science Conference, a world-leading medical cannabis event. It will serve as an opportunity to showcase Apollon's compelling third-party testing results which showed its proprietary medical cannabis formulations successfully killing nearly 100% of prostate, triple negative and HER2+ breast cancer cells in 3D cell cultures. This endorsement by CSC is significant for Apollon, as it further strengthens our credibility and will improve our visibility, particularly in North America."
Interested parties can register for the event via the website: www.cannabisscienceconference.com
We seem to be loosing ground now
MrTHC long time no see, trust you're well.................
Acquisition of Citiva Jamaica LLC and Collaboration Agreement with University of West Indies
Director Loan Agreement
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK-based international pharmaceutical company trading on the Aquis Stock Exchange, is delighted to announce that its Jamaican affiliate, Apollon Formularies Jamaica Ltd ("Apollon Jamaica"), has reached an agreement to acquire Citiva Jamaica LLC ("Citiva Jamaica") (the "Acquisition") in a part-cash, part-shares transaction.
The Acquisition of Citiva Jamaica, originally started by Josh Stanley, Co-Founder of Charlotte's Web, gives Apollon Jamaica ownership of a world class research, cultivation, manufacturing and processing facility, affiliated with, and located in the Medical School of the University of West Indies ("UWI") campus. The Acquisition delivers on Apollon's previously stated desire to become a vertically integrated, globally recognised medical cannabis business providing treatments and medicines for various human afflictions with a specific focus on cancer.
Transaction Highlights:
• Apollon Jamaica has acquired a university-affiliated, world class research, cultivation, manufacturing, and processing facility for medical grade cannabis
• Citiva Jamaica's facilities give the Company a clear path to large scale manufacturing of high-quality medical grade, full and broad-spectrum oils with GMP certification for use in its patent protected cancer, chronic pain and inflammation treatments, including for international marketing and distribution
• Importantly, Apollon can now achieve the final approval step with the Ministry of Health and Wellness in Jamaica to distribute its patented cannabis based medical products into the Jamaican national pharmacy and dispensary network, the broader Caribbean Community ("CARICOM"), the Southern African Development Community ("SADC") as well as other targeted markets globally
• The Citiva Jamaica facility comes with a Cannabis License Authority (CLA) issued Cultivation Licence, extensive indoor cultivation facilities with cannabis cultivars currently growing and nearing harvest time, approximately 30-35 kg of processed full spectrum medical cannabis oil, and processing equipment
• Under the terms of the arrangement, Apollon Jamaica will acquire a 96% ownership of Citiva Jamaica (in stages), with UWI potentially holding 10% subject to the Company offering them an increase from 4% to 10%
• Expected to create significant revenue growth for the Company over the next 12 months
In consideration for the Acquisition, Apollon will pay US$60,000 cash as well as issue 18,465,910 new Ordinary Shares in Apollon to CJL Holdings, a US based group. The shares will be subject to a nine-month, orderly market, lock-in agreement with one third of the shares becoming unrestricted after each 3-month period from the transaction date. Following compl
Years of talk and no sales........................
(1/2) This weekend marks six months since #Apollon announced the signing of over a dozen tripartite agreements with
@cla_jamaica
licensed cultivators to help accelerate production of #APOL's proprietary #medicalcannabis formulations ??http://ow.ly/oY4650JRgUc
9:33 AM · Jul 8, 2022·Hootsuite Inc.
2/2) The agreements are a mutually beneficial, providing #Apollon with a continuous supply of high-quality #cannabis buds while allowing Jamaican farmers to grow their businesses, with the hopes to further develop #Jamaica’s #medicalcannabis industry ??????
9:39 AM · Jul 8, 2022·Hootsuite Inc.
https://polaris.brighterir.com/public/apollon_formularies/news/rns/story/xjjkjox
The sooner the better................ IMHO
Apollon Formularies
@apollon_uk
·
28m
The combination of our licenses provide us with an opportunity to continue to successfully implement our business plan & achieve the goal of developing, processing, and manufacturing #APOL proprietary formulations & selling cannabis derived pharmaceutical & nutraceutical products
https://twitter.com/apollon_uk
All for helping the local farmer's, sounds great to me...................
Apollon Formularies
@apollon_uk
·
14m
#APOL believes in elevating Jamaica's global position in the #medicalcannabis industry, and achieving this includes valuing the knowledge the local cultivators have to offer. We believe that those we have signed agreements with should not just grow for us, but grow with us
https://twitter.com/apollon_uk
Capacity is not sales................ LOL
January 2022.............
which has the capacity to produce roughly 20 litres of full-spectrum medical cannabis oil per day.
https://www.proactiveinvestors.co.uk/companies/news/970527/apollon-formularies-gets-green-light-for-jamaica-medical-cannabis-licence-renewal-970527.html